CVRx  

9201 W. Broadway Ave.
Suite 650
Minneapolis,  MN  55445

United States
http://www.cvrx.com/
  • Booth: 1401


www.cvrx.com

CVRx's Barostim is the first medical technology approved by the FDA that uses neuromodulation - the power of the brain and nervous system - to improve the symptoms of patients with systolic heart failure. Barostim works by electrically activating carotid baroreceptors and, in turn, the baroreflex. This signals the autonomic nervous system to regulate heart, kidney and vascular function through both sympathetic and parasympathetic pathways. Barostim received the FDA Breakthrough Device Designation and is FDA-approved for use in heart failure patients in the US.


 Products

  • Barostim
    Barostim is a new option for HFrEF patients that uses autonomic stimulation to improve symptoms.

    ...

  • Barostim Rebalances the Autonomic Nervous System

    Barostim works by electrically activating carotid baroreceptors and, in turn, the baroreflex. This signals the autonomic nervous system to regulate heart, kidney and vascular function through both sympathetic and parasympathetic pathways.

    Barostim Indications

    • NYHA III or NYHA II (with recent NYHA III) on GDMT*
    • LVEF < 35%
    • Not indicated for CRT**
    • NT-proBNP < 1,600 pg/mL
       

    *Guideline directed medical therapy (GDMT) according to AHA/ACC/ESC guidelines
    **Or not receiving adequate response from existing CRT device